# A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

> **NCT00517283** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 17 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** exenatide and placebo
- **DRUG:** Exenatide and placebo
- **DRUG:** Exenatide and placebo

## Key facts

- **NCT ID:** NCT00517283
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2015-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00517283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00517283, "A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00517283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*